SEC Company Response from Salarius Pharmaceuticals, Inc. (DCOY) (CIK 0001615219) (DCOY) — Aug 8, 2025
Salarius Pharmaceuticals, Inc. (DCOY) (CIK 0001615219)
Date: Aug. 8, 2025 · CIK: 0001615219 · Accession: 0001615219-25-000091
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-284368
Letter
Document
Ladenburg Thalmann & Co. Inc.
640 Fifth Avenue, 4th Floor
New York, New York 10019
August 8, 2025
VIA EDGAR
Office of Life Sciences
Division of Corporation Finance
U.S. Securities and Exchange Commission
100 F Street, N.E.
Washington, DC 20549
Re: Salarius Pharmaceuticals, Inc.
Registration Statement on Form S-1 (Registration No. 333-284368)
Concurrence in Acceleration Request
Ladies and Gentlemen:
Ladenburg Thalmann & Co. Inc. (“Ladenburg”), as representative of the underwriters for the referenced offering, hereby concurs in the request by Salarius Pharmaceuticals, Inc. that the effective date of the above-referenced registration statement be accelerated to 9:00 a.m. (Eastern Time), or as soon as practicable thereafter, on August 11, 2025, pursuant to Rule 461 under the Securities Act. Ladenburg affirms that it is aware of its obligations under the Securities Act in connection with this offering.
Very truly yours,
LADENBURG THALMANN & CO. INC.
Show Raw Text
CORRESP
1
filename1.htm
Document
Ladenburg Thalmann & Co. Inc.
640 Fifth Avenue, 4th Floor
New York, New York 10019
August 8, 2025
VIA EDGAR
Office of Life Sciences
Division of Corporation Finance
U.S. Securities and Exchange Commission
100 F Street, N.E.
Washington, DC 20549
Re: Salarius Pharmaceuticals, Inc.
Registration Statement on Form S-1 (Registration No. 333-284368)
Concurrence in Acceleration Request
Ladies and Gentlemen:
Ladenburg Thalmann & Co. Inc. (“Ladenburg”), as representative of the underwriters for the referenced offering, hereby concurs in the request by Salarius Pharmaceuticals, Inc. that the effective date of the above-referenced registration statement be accelerated to 9:00 a.m. (Eastern Time), or as soon as practicable thereafter, on August 11, 2025, pursuant to Rule 461 under the Securities Act. Ladenburg affirms that it is aware of its obligations under the Securities Act in connection with this offering.
Very truly yours,
LADENBURG THALMANN & CO. INC.
By: /s/ Nicholas Stergis
Name: Nicholas Stergis
Title: Managing Director